Logo Image
News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsEventsSponsored PodcastsSponsored VideosWebcastsWhitepaperseBooks
Event Calendar

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Event Calendar
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2026|
Sales Effectiveness
Advertisement

Mark Pelletier

Advertisement

Articles by Mark Pelletier

Five Features to Ensure Lab-ready Buildings

ByMark Pelletier
September 11th 2018

Pharmaceutical Executive

A list of five essential features a building must have in order to be considered lab-ready.

Advertisement

Latest Updated Articles

  • Five Features to Ensure Lab-ready Buildings
    Five Features to Ensure Lab-ready Buildings

    September 11th 2018



Advertisement
Advertisement

Trending on PharmExec

1

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

2

Pharmaceutical Executive Daily: FDA Approves Hibsago

3

CSL Names Deborah Waterhouse as CEO and Manager Director

4

Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds

5

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us